It would depend in how many indications leronlimab
Post# of 148183
(Total Views: 464)
Posted On: 01/01/2020 11:11:42 PM
Re: crazyjogger925 #14086
It would depend in how many indications leronlimab works and whether we commercialize alone or what deals we can make.
If leronlimab works in all of most likely indications - Before the current deal was announced, based on 700m shares, our own commercialization in U.S. and waiting out overseas deals for optimal return (40% net sales) I cranked out a fast and loose $300 per share. With HIV off the table, maybe $260 per share. If we set deals for other indications, share price will be determined by the terms of the deals.
If leronlimab works in all of most likely indications - Before the current deal was announced, based on 700m shares, our own commercialization in U.S. and waiting out overseas deals for optimal return (40% net sales) I cranked out a fast and loose $300 per share. With HIV off the table, maybe $260 per share. If we set deals for other indications, share price will be determined by the terms of the deals.
(1)
(0)CytoDyn Inc (CYDY) Stock Research Links
Scroll down for more posts ▼